Several randomized studies have also revealed that reversible EGFR-TKIs such as erlotinib and gefitinib are superior to standard chemotherapy with regard to progression-free survival, as well as progression-free survival in patients with NSCLC with EGFR sensitive mutations [6–10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.